BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9209471)

  • 41. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
    Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
    Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
    Beroukhim R; Brunet JP; Di Napoli A; Mertz KD; Seeley A; Pires MM; Linhart D; Worrell RA; Moch H; Rubin MA; Sellers WR; Meyerson M; Linehan WM; Kaelin WG; Signoretti S
    Cancer Res; 2009 Jun; 69(11):4674-81. PubMed ID: 19470766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma.
    Neumann HP; Bender BU; Berger DP; Laubenberger J; Schultze-Seemann W; Wetterauer U; Ferstl FJ; Herbst EW; Schwarzkopf G; Hes FJ; Lips CJ; Lamiell JM; Masek O; Riegler P; Mueller B; Glavac D; Brauch H
    J Urol; 1998 Oct; 160(4):1248-54. PubMed ID: 9751329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
    Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
    Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
    Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
    Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Familial adult renal neoplasia.
    Takahashi M; Kahnoski R; Gross D; Nicol D; Teh BT
    J Med Genet; 2002 Jan; 39(1):1-5. PubMed ID: 11826016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics of renal cell carcinoma in Korean patients with von Hippel-Lindau disease compared to sporadic bilateral or multifocal renal cell carcinoma.
    Kim WT; Ham WS; Ju HJ; Lee JS; Lee JS; Choi YD
    J Korean Med Sci; 2009 Dec; 24(6):1145-9. PubMed ID: 19949673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body mass index and von Hippel-Lindau gene mutations in clear-cell renal cancer: Results of the Netherlands Cohort Study on diet and cancer.
    Smits KM; Schouten LJ; Hudak E; Verhage B; van Dijk BA; Hulsbergen-van de Kaa CA; Goldbohm RA; Oosterwijk E; van den Brandt PA
    Ann Epidemiol; 2010 May; 20(5):401-4. PubMed ID: 20382342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
    Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
    Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.
    Petrella BL; Brinckerhoff CE
    Mol Cancer; 2006 Dec; 5():66. PubMed ID: 17140440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma.
    Shuib S; Wei W; Sur H; Morris MR; McMullan D; Rattenberry E; Meyer E; Maxwell PH; Kishida T; Yao M; Latif F; Maher ER
    Genes Chromosomes Cancer; 2011 Jul; 50(7):479-88. PubMed ID: 21456047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Analysis of biallelic inactivation of the von Hippel-Lindau tumor suppressor gene VHL in patients of renal cell carcinoma patient].
    Liu N; Gong K; Zhang N; Guo HF; Na X; Wu G; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):115-7. PubMed ID: 15771820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.
    Decker HJ; Neuhaus C; Jauch A; Speicher M; Ried T; Bujard M; Brauch H; Störkel S; Stöckle M; Seliger B; Huber C
    Hum Genet; 1996 Jun; 97(6):770-6. PubMed ID: 8641695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
    Peruzzi B; Athauda G; Bottaro DP
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.